3-(2-chloro-5-fluoro-pyrimidin-4-yl)-6-fluoro-imidazo[1,2-a]pyridine | 1224707-64-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并吡啶类
• 英文名称: 3-(2-chloro-5-fluoro-pyrimidin-4-yl)-6-fluoro-imidazo[1,2-a]pyridine
• 英文别名: 3-(2-Chloro-5-fluoropyrimidin-4-yl)-6-fluoroimidazo[1,2-a]pyridine
• CAS: 1224707-64-5
• 化学式: C₁₁H₅ClF₂N₄
• 分子量: 266.637
• InChiKey: YWNVARLCBQDEBK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  18
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  43.1
• 氢给体数：
  0
• 氢受体数：
  5

文献信息

• [EN] DERIVATIVES OF 4-(IMIDAZO[L,2-A]PYRIDIN-3-YL)-N-(PYRIDINYL)PYRIMIDIN- 2-AMINE AS THERAPEUTIC AGENTS<br/>[FR] DÉRIVÉS DE 4-(IMIDAZO [L, 2-A] PYRIDINE-3-YL)-N-(PYRIDINYL) PYRIMIDINE-2-AMINE EN TANT QU'AGENTS THÉRAPEUTIQUES
  申请人：AUCENTRA THERAPEUTICS PTY LTD

  公开号：WO2021003517A1

  公开（公告）日：2021-01-14

  A novel class of heteroaryl compounds for use in the prevention and/or treatment of proliferative diseases and conditions including cancers. The compounds are considered to be capable of inhibiting cell proliferation by inhibiting the activity of FLT3 and its mutant forms and/or other protein kinases such as CDKs. The compounds have the general structure I:

  一类新型的杂环芳基化合物，用于预防和/或治疗包括癌症在内的增生性疾病和症状。这些化合物被认为能够通过抑制FLT3及其突变形式和/或其他蛋白激酶如CDK的活性来抑制细胞增殖。这些化合物具有一般结构I：
• NOVEL COMPOUNDS 515
  申请人：Ducray Richard

  公开号：US20100105655A1

  公开（公告）日：2010-04-29

  There is provided novel pyrimidine derivatives of formula (I) or pharmaceutically acceptable salts thereof, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.

  提供了化学式（I）的新型嘧啶衍生物或其药用盐，以及它们的制备方法、含有它们的药物组合物以及它们在治疗中的应用。
• Derivatives of N-cycloalkyl/heterocycloalkyl-4-(imidazo[1,2-a]pyridine)pyrimidin-2-amine as therapeutic agents
  申请人：Aucentra Therapeutics Pty Ltd

  公开号：US11111245B2

  公开（公告）日：2021-09-07

  A novel class of inhibitors of protein kinases that are useful in the treatment of cell proliferative diseases and conditions, and especially those characterised by over-expression of one or more CDK enzyme and/or by one or more aberrant CDK activity, including certain cancers of lung, breast, brain, ovary, prostate, colorectal cancer and leukaemias. The inhibitors have the general structure (I).

  一类新型蛋白激酶抑制剂，可用于治疗细胞增殖性疾病和病症，特别是以一种或多种 CDK 酶过度表达和/或一种或多种 CDK 活性异常为特征的疾病和病症，包括某些肺癌、乳腺癌、脑癌、卵巢癌、前列腺癌、结直肠癌和白血病。这些抑制剂具有一般结构 (I)。
• DERIVATIVES OF 4-(IMIDAZO[L,2-A]PYRIDIN-3-YL)-N-(PYRIDINYL)PYRIMIDIN- 2-AMINE AS THERAPEUTIC AGENTS
  申请人：Aucentra Therapeutics Pty Ltd

  公开号：EP3997088A1

  公开（公告）日：2022-05-18
• DERIVATIVES OF N-CYCLOALKYL/HETEROCYCLOALKYL-4-(IMIDAZO[1,2-a]PYRIDINE)PYRIMIDIN-2-AMINE AS THERAPEUTIC AGENTS
  申请人：Aucentra Therapeutics Pty Ltd

  公开号：US20200231586A1

  公开（公告）日：2020-07-23

  A novel class of inhibitors of protein kinases that are useful in the treatment of cell proliferative diseases and conditions, and especially those characterised by over-expression of one or more CDK enzyme and/or by one or more aberrant CDK activity, including certain cancers of lung, breast, brain, ovary, prostate, colorectal cancer and leukaemias. The inhibitors have the general structure (I).